Add to My Stocks
Yew Bio Pharm Revenue Chart
$0.35 $0 (0%) YEWB stock closing price Jun 19, 2018 (Closing)
The latest 2018-Q1 Yew Bio Pharm revenue is 3.03M. Compare Yew Bio Pharm revenue chart with Ricebran revenue, AGEAGLE AERIAL revenue.
YEWB Revenue Chart
You can do annual as well as quarterly comparisons of Yew Bio-Pharm Group, Inc. net sales with its competitor companies like Ricebran, AGEAGLE AERIAL. Over the 5 year period Yew Bio Pharm revenue in 2016 was highest at 51.34M. In the latest quarter, YEWB revenue 2018-Q1 has changed from 5.5M to 3.03M implying a decrease of 44.91%.
Yew Bio Pharm Quarterly Revenue
* Past 5 years Range
|Max YEWB Revenue||$17.27M||Dec, 2015|
|Min YEWB Revenue||$1.54M||Sep, 2013|
Yew Bio Pharm Annual Revenue
* Past 5 years Range
|Max YEWB Revenue||$51.34M||Dec, 2016|
|Min YEWB Revenue||$7.43M||Dec, 2013|
Yew Bio Pharm Annual Revenue VS Peers
|Yew Bio Pharm Revenue||$40.53M||$51.34M||$29.57M||$7.72M||$7.43M|
|AGEAGLE AERIAL Revenue||$1.32M||$2.46M||$4.87M||$14.29M||$10.94M|
|Origin Agritech Revenue||----||$50.2M||$59.14M||$67.52M||$77.29M|
|Pope Resources Revenue||$99.82M||$80.42M||$78.02M||$87.47M||$70.69M|
|Fibria Celulose Revenue||$3.68B||$2.76B||$3.08B||$3.03B||$3.22B|
Yew Bio Pharm Stock Articles
Revenue or net sales, also called topline or gross income is one of the most important financial metrics used to analyze a company. Revenue is the total amount of money that a company brings in through its various business activities, and appears as the ‘top line’ on the income statement. A company's net sales for a particular period can be found in its income statement. A healthy growth in revenue over time is generally considered good for the company, however other parameters such as profits must also be considered. We can calculate Yew Bio Pharm profits by subtracting expenses from Yew Bio Pharm revenue. Apart from analyzing a company's revenues over the years, it also helps to compare Yew Bio Pharm revenue with peers YIELD10 BIOSCI topline, China Modern topline, Grow Solutions topline; to see how the company is doing with respect to its peers.